Regend Therapeutics

The phase I clinical trial of lung progenitor cell product REGEND001 for chronic obstructive pulmonary disease was elected as one of the top three annual progresses by the European Respiratory Society in 2023. REGEND001 has shown improvement in gas transfer capacity, lung capacity, life quality, functional exercise capacity, and other lung function measures in patients with various chronic pulmonary diseases. It has successfully repaired damaged lung structures, diminished emphysema lesions in COPD, reduced broncho-arterial ratio and inflammatory areas in bronchiectasis, and resolved fibrotic tissues in idiopathic pulmonary fibrosis.[1]